ClinicalTrials.gg
CompletedNCT02007512Updated Sep 2, 2025Results posted

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

A Phase 2 interventional study of Enzalutamide and exemestane in Breast Cancer, sponsored by Pfizer. Completed at 135 sites in 7 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-02.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
247
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing enzalutamide in Breast Neoplasms — 1 open to participants now, 3 under way, none of them phase 3. enzalutamide · Breast Neoplasms.

Enrollment
Largest of 13
247 · median 61
Started
2013
with 1 other
Phase 2
9 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing enzalutamide in Breast Neoplasms, this one has the largest enrollment, is one of 2 that started in 2013, is one of 9 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 13 studies testing enzalutamide in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing enzalutamide in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine if enzalutamide given in combination with exemestane is safe and effective in patients with advanced breast cancer.

Read the detailed description

This is a Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor Positive and HER2-Normal.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • advanced breast cancer
  • enzalutamide
  • MDV3100
  • Estrogen receptor positive (ER +)
  • Progesterone receptor positive (PgR +)
  • HER-2 normal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide ;
  • ;
  • Advanced confirmed breast cancer that is ER+, PgR+, or both, and normal;
  • Up to one prior hormone therapy and up to one prior chemotherapy in the advanced setting is allowed;
  • Availability of a representative, formalin-fixed, paraffin-embedded tumor specimen that enabled the diagnosis of breast cancer with viable tumor cells in a tissue block or unstained serial slides accompanied bay an associated pathology report;
  • . Patients with non-measurable bone or skin disease as their only manifestation of advanced breast cancer are also eligible;
  • (ECOG) status of 0 or 1;

Exclusion criteria

Exclusion Criteria:

  • Any severe concurrent disease, infection, or comorbid condition that renders the patient inappropriate for enrollment in the opinion of the investigator;
  • Any condition or reason that interferes with the patient's ability to participate in the trial, that may cause undue risk, or complicates the interpretation of safety data, in the opinion of the investigator;
  • Current or previously treated or ;
  • Prior therapy (> 28 days) with exemestane in the setting (Patients receiving exemestane in the setting and having disease recurrence more than 1 year after treatment discontinuation are eligible);
  • Requires treatment for tuberculosis or infection;
  • Radiation therapy within 7 days before randomization;
  • History of another invasive cancer within 5 years before randomization;
  • History of seizure or any condition that may predispose to seizure;
  • cardiovascular disease;
  • Active gastrointestinal disorder;
  • Major surgery within 28 days prior to randomization;
  • Treatment with any oral anticancer or with any non-hormonal anticancer agent within 14 days before randomization;
  • Treatment with any approved or agent that blocks androgen synthesis or targets the androgen receptor;
  • Treatments with any of the following medications within 14 days before randomization: Estrogens, Androgens, or Systemic radionuclides;
  • reaction to exemestane.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
247 participants (actual)

Study arms

  • Experimental
    Enzalutamide & exemestane

    Enzalutamide 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food and exemestane 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) once daily after food.

    Drug: Enzalutamide · Drug: exemestane

  • Active comparator
    Placebo & exemestane

    Placebo and exemestane 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet without placebo after unblinding) once daily after food.

    Drug: exemestane · Drug: Placebo (for enzalutamide)

Interventions

  • 160 mg/day administered as four 40mg soft gelatin capsules by mouth once daily with or without food.

    Also known as: MDV3100, XTANDI

  • 25mg (overencapsulated to match 50mg dose during the blinded portion of the study and one 25mg tablet after unblinding) by mouth once daily after food.

    Also known as: Aromasin

  • DrugPlacebo (for enzalutamide)

    Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.

  • 50mg (two 25mg tablets overencapsulated as a single capsule during the blinded portion of the study and two 25mg tablets after unblinding) by mouth once daily after food.

    Also known as: Aromasin

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)

    PFS was defined as the time in months from randomization to the first documentation of progression of disease (PD) or death on study due to any cause, whichever occurred first. PD according to response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) was defined as greater than or equal to (\>=) 20 percent (%) increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

    Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)

  2. Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)

    PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

    Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)

Secondary outcomes

  1. Clinical Benefit Rate-24 (CBR-24)

    CBR-24: Percentage of participants with a best response of complete response (CR), partial response (PR), or stable disease (SD) sustained for atleast 24 weeks, as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (less than \[\<\] 10 millimeter \[mm\] short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during study as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions.

    Time frame: From randomization up to 3 years

  2. Best Objective Response Rate

    Best objective response rate: Percentage of participants with measurable disease and with a best response of CR or PR according to RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: Atleast 30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. Response evaluation was based on investigators' judgment.

    Time frame: From randomization until CR or PR, whichever occurred first (up to 3 years)

  3. Duration of Objective Response

    Duration of objective response: Time from first documentation of CR or PR, to the first documentation of PD or death due to any cause, whichever occurred first as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants with no PD or death (after initial CR or PR) at the analysis date were censored at last tumor assessment date prior to date of new antitumor treatment or data cutoff.

    Time frame: From first documentation of CR or PR until PD, or last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)

  4. Time to Response

    Time to response: Time from randomization to first documentation of CR or PR. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who were not known to have had a CR or PR were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

    Time frame: From randomization until first documentation of CR or PR, or last tumor assessment without PD or death prior to new antitumor treatment initiation, whichever occurred first (up to 3 years)

  5. Time to Progression

    Time to progression was defined as the time from the date of randomization to PD defined by the investigator using RECIST 1.1. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who did not experience disease progression, time to progression was right censored at the date of the last tumor assessment prior to data cutoff or date of new antitumor treatment, whichever occurred first.

    Time frame: From randomization until PD or last tumor assessment without PD before new antitumor treatment initiation, whichever occurred first (up to 3 years)

  6. Progression Free Survival (PFS) at 6 Months

    PFS at 6 months was defined as the percentage of participants with no event of disease progression at Month 6 landmark, estimated by Kaplan-Meier methods. PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. The analysis of PFS was based on investigator assessment of disease progression.

    Time frame: Month 6

  7. Concentration Versus Time Summary of Enzalutamide

    Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

    Time frame: Predose on Day 29, 57 and 113

  8. Concentration Versus Time Summary of Exemestane

    Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

    Time frame: Predose, 1 and 6 hour postdose on Day 29, 57, 113 and 169

  9. Concentration Versus Time Summary of N-desmethyl Enzalutamide

    N-desmethyl enzalutamide was the active metabolite of enzalutamide. Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

    Time frame: Predose on Day 29, 57 and 113

Other outcomes

  1. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Core Questionnaire (QLQ-C30) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133: Global Health/Quality of Life

    The EORTC QLQ-C30 questionnaire was a standardized instrument developed to assess the quality of life of people with cancer. Participants self-rated their self-care, activity level, pain/discomfort, and mental health during the past week by choosing 1 of 4 possible responses that recorded the level of intensity (not at all, a little, quite a bit, and very much) within each dimension, where higher score=more level of intensity. The questionnaire also asked the participants to rate their overall health or quality of life within the past week on a scale of 1 to 7, where 1 is "very poor" and 7 is "excellent". Higher global health or quality of life scores indicated better overall health or quality of life. In this outcome measure, global health/quality of life scores are presented.

    Time frame: Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133

  2. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Module (QLQ-BR23) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133

    EORTC QLQ-BR23 was disease-specific module for breast cancer developed as supplement for EORTC QLQ-C30 that assessed quality of life of participants with breast cancer.Participants self-rated on frequent symptoms or problems reported by participants with breast cancer,e.g., pain/discomfort, body satisfaction, and self-esteem during past week by choosing 1 of 4 possible responses that recorded level of intensity (not at all, a little, quite a bit, and very much) within each dimension.Raw scores were then transformed to 0-100 scale for analysis and interpretation, where higher scores=more level of intensity, as per EORTC guidelines.Participants also self-rated on sexual health/interest during last 4 weeks using same scale. In this outcome measure body image functioning, sexual functioning, systemic therapy side effects, upset by hair loss parameters were assessed by EORTC QLQ-BR23 questionnaire,total score for each parameter ranged from 0-100,where higher scores=more level of intensity.

    Time frame: Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133

  3. Number of Participants With Positive Androgen Receptor (AR) Expression by Immunohistochemistry (IHC)

    Time frame: Day 1, 29, 57, 113 and 169

  4. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)

  5. Number of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only the participants with treatment-emergent AEs of grade 3 (severe) or higher grade were reported in this outcome measure.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)

  6. Number of Participants With Clinically Significant Vital Sign Abnormalities

    Criteria for clinically significant vital sign abnormalities: Systolic blood pressure (SBP): absolute SBP \<90 millimeters of mercury (mmHg) and decrease from baseline (DFB) \>30 mmHg, absolute SBP\>180 mmHg and increase from baseline (IFB) \>40 mmHg, final visit or 2 consecutive visits SBP \>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP \>=140 mmHg, most extreme post-baseline SBP \>=180 mmHg, most extreme SBP \>=140 mmHg and \>=20 mmHg CFB, most extreme SBP \>=180 mmHg and \>=20 mmHg CFB; diastolic blood pressure (DBP): absolute DBP \> 105 mmHg and IFB \>30 mmHg, absolute DBP \<50 mmHg and DFB \>20 mmHg, final visit or 2 consecutive visits DBP \>=15 mmHg CFB, most extreme post-baseline DBP \>=90 mmHg, most extreme post-baseline DBP \>=105 mmHg, most extreme DBP \>=90 mmHg and \>=15 mmHg CFB, most extreme DBP \>=105 mmHg and \>=15 mmHg CFB; heart rate \<50 beats per minute (BPM) and DFB \>20 BPM or heart rate \>120 BPM and IFB \>30 BPM.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)

  7. Number of Participants With Clinically Significant Laboratory Abnormalities

    Laboratory tests included hematology (hematocrit, hemoglobin, platelet count, red blood cell count, total neutrophils \[absolute\] and white blood cell count with differential) and serum chemistry (albumin, alkaline phosphatase, alanine aminotransferase \[ALT\], aspartate transaminase \[AST\], blood urea nitrogen and creatinine, calcium, sodium, potassium, chloride, glucose (non-fasting), lactate dehydrogenase, magnesium, phosphorus/phosphate, total bilirubin, total bicarbonate, total protein and uric acid). Clinically significant abnormality evaluation was based on clinical investigator's judgment.

    Time frame: Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (up to 3 years)

  8. Progression Free Survival (PFS): By Electronic Data Capture (EDC)

    PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1 was defined \>=20 % increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first. Cht 1: Enz + Exe = Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg; Cht 2: Enz + Exe= Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg

    Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)

  9. Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC)

    PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

    Time frame: From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)

07

Results

Posted Feb 6, 2018

Participant flow

A total of 247 participants were enrolled.

Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
MilestoneCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Placebo + Exemestane 25 mg
Started63606460
Treated62606360
Completed0000
Not completed63606460
Withdrew: Adverse event4622
Withdrew: Death1000
Withdrew: Disease progression51505752
Withdrew: Withdrawal by subject3333
Withdrew: Protocol violation1001
Withdrew: Other2112
Withdrew: Randomized but not treated1010
Open Label Treatment Period
Participant flow — Open Label Treatment Period
MilestoneCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Placebo + Exemestane 25 mg
Started251200
Treated241100
Completed0000
Not completed251200
Withdrew: Adverse event1000
Withdrew: Other1100
Withdrew: Disease progression231100

Outcome measures

PrimaryProgression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)

PFS was defined as the time in months from randomization to the first documentation of progression of disease (PD) or death on study due to any cause, whichever occurred first. PD according to response evaluation criteria in solid tumors version 1.1 (RECIST 1.1) was defined as greater than or equal to (\>=) 20 percent (%) increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

Time frame:
From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Reported as:
Median · months
Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)
monthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Progression Free Survival (PFS): Intent-to-Treat (ITT) Population By Interactive Web Recognition System (IWRS)11.8 (7.3 to 15.9)5.8 (3.5 to 10.9)3.6 (1.9 to 5.5)3.9 (2.6 to 5.4)
Statistical analysis
  • Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 1: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.3631 · Hazard ratio (hr): 0.820 · 95% CI 0.535 to 1.257
  • Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 2: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.9212 · Hazard ratio (hr): 1.022 · 95% CI 0.659 to 1.586
PrimaryProgression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)

PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

Time frame:
From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Reported as:
Median · months
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)
monthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Interactive Web Recognition System (IWRS)16.5 (11.0 to NA)4.3 (1.9 to 10.9)6.0 (2.3 to 26.7)5.3 (1.8 to 6.7)
Statistical analysis
  • Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 1: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.0335 · Hazard ratio (hr): 0.442 · 95% CI 0.205 to 0.955
  • Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 2: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.1936 · Hazard ratio (hr): 0.554 · 95% CI 0.225 to 1.363
SecondaryClinical Benefit Rate-24 (CBR-24)

CBR-24: Percentage of participants with a best response of complete response (CR), partial response (PR), or stable disease (SD) sustained for atleast 24 weeks, as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (less than \[\<\] 10 millimeter \[mm\] short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. SD: Neither sufficient reduction to qualify as PR nor sufficient increase to qualify as PD, using the smallest sum diameters during study as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions.

Time frame:
From randomization up to 3 years
Reported as:
Number · percentage of participants
Clinical Benefit Rate-24 (CBR-24)
percentage of participantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Clinical Benefit Rate-24 (CBR-24)61.9 (48.8 to 73.9)45.3 (32.8 to 58.3)20.0 (10.8 to 32.3)31.7 (20.3 to 45.0)
SecondaryBest Objective Response Rate

Best objective response rate: Percentage of participants with measurable disease and with a best response of CR or PR according to RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: Atleast 30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. Response evaluation was based on investigators' judgment.

Time frame:
From randomization until CR or PR, whichever occurred first (up to 3 years)
Reported as:
Number · percentage of participants
Best Objective Response Rate
percentage of participantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Best Objective Response Rate30.8 (17.0 to 47.6)19.0 (8.6 to 34.1)9.5 (2.7 to 22.6)4.8 (0.6 to 16.2)
SecondaryDuration of Objective Response

Duration of objective response: Time from first documentation of CR or PR, to the first documentation of PD or death due to any cause, whichever occurred first as determined by investigator using RECIST 1.1. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants with no PD or death (after initial CR or PR) at the analysis date were censored at last tumor assessment date prior to date of new antitumor treatment or data cutoff.

Time frame:
From first documentation of CR or PR until PD, or last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Reported as:
Median · months
Duration of Objective Response
monthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Duration of Objective Response14.0 (5.6 to NA)9.1 (3.2 to 10.2)18.3 (3.3 to 23.1)4.6 (1.9 to 7.4)
SecondaryTime to Response

Time to response: Time from randomization to first documentation of CR or PR. CR: Disappearance of all (target and non-target) lesions and normalization of tumor marker level for non-target lesions. All lymph nodes (target and non-target) must be non-pathological in size (\<10 mm short axis). PR: \>=30% decrease in sum of diameters of target lesions, using baseline sum diameters as reference. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who were not known to have had a CR or PR were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

Time frame:
From randomization until first documentation of CR or PR, or last tumor assessment without PD or death prior to new antitumor treatment initiation, whichever occurred first (up to 3 years)
Reported as:
Median · months
Time to Response
monthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Time to Response12.9 (7.3 to NA)14.0 (7.4 to NA)NA (3.9 to NA)NA (NA to NA)
SecondaryTime to Progression

Time to progression was defined as the time from the date of randomization to PD defined by the investigator using RECIST 1.1. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. Participants who did not experience disease progression, time to progression was right censored at the date of the last tumor assessment prior to data cutoff or date of new antitumor treatment, whichever occurred first.

Time frame:
From randomization until PD or last tumor assessment without PD before new antitumor treatment initiation, whichever occurred first (up to 3 years)
Reported as:
Median · months
Time to Progression
monthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Time to Progression11.8 (7.3 to 15.9)7.4 (3.5 to 13.5)3.6 (1.9 to 5.6)3.9 (2.6 to 5.4)
SecondaryProgression Free Survival (PFS) at 6 Months

PFS at 6 months was defined as the percentage of participants with no event of disease progression at Month 6 landmark, estimated by Kaplan-Meier methods. PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD: \>=20% increase (an absolute increase of \>=5 mm) in sum of diameters of target lesions, using the smallest sum during the study as a reference (including baseline sum), or unequivocal progression of existing non-target lesions, or appearance of atleast 1 new target or non-target lesions. The analysis of PFS was based on investigator assessment of disease progression.

Time frame:
Month 6
Reported as:
Number · percentage of participants
Progression Free Survival (PFS) at 6 Months
percentage of participantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Progression Free Survival (PFS) at 6 Months66.7 (53.2 to 77.0)50.0 (37.1 to 61.6)31.5 (19.7 to 43.9)33.3 (21.6 to 45.5)
SecondaryConcentration Versus Time Summary of Enzalutamide

Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

Time frame:
Predose on Day 29, 57 and 113
Reported as:
Mean · microgram per milliliter
Concentration Versus Time Summary of Enzalutamide
microgram per milliliterEnzalutamide 160 mg
Day 2914.2 ± 2.97
Day 5714.2 ± 3.21
Day 11313.2 ± 4.51
SecondaryConcentration Versus Time Summary of Exemestane

Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

Time frame:
Predose, 1 and 6 hour postdose on Day 29, 57, 113 and 169
Reported as:
Mean · Picogram per milliliter
Concentration Versus Time Summary of Exemestane
Picogram per milliliterExemestane 25 mgExemestane 50 mg
Day 29: Predose1010 ± 1600943 ± 939
Day 29: 1 hour Postdose17000 ± 1640019200 ± 17800
Day 29: 6 hour Postdose5590 ± 47506850 ± 9090
Day 57: Predose1160 ± 25901100 ± 2650
Day 57: 1 hour Postdose19900 ± 1860015300 ± 14500
Day 57: 6 hour Postdose5890 ± 48805650 ± 6200
Day 113: Predose1160 ± 28701330 ± 3380
Day 113: 1 hour Postdose20800 ± 1810019400 ± 18500
Day 113: 6 hour Postdose3510 ± 38505600 ± 5290
Day 169: 1 hour Postdose—22800 ± NA
Day 169: 6 hour Postdose—6020 ± NA
SecondaryConcentration Versus Time Summary of N-desmethyl Enzalutamide

N-desmethyl enzalutamide was the active metabolite of enzalutamide. Concentration versus time summary was calculated by setting concentration values below limit of quantitation to zero.

Time frame:
Predose on Day 29, 57 and 113
Reported as:
Mean · microgram per milliliter
Concentration Versus Time Summary of N-desmethyl Enzalutamide
microgram per milliliterEnzalutamide 160 mg
Day 2911.6 ± 4.10
Day 5715.2 ± 4.76
Day 11315.2 ± 5.81
Other pre-specifiedChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Core Questionnaire (QLQ-C30) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133: Global Health/Quality of Life

The EORTC QLQ-C30 questionnaire was a standardized instrument developed to assess the quality of life of people with cancer. Participants self-rated their self-care, activity level, pain/discomfort, and mental health during the past week by choosing 1 of 4 possible responses that recorded the level of intensity (not at all, a little, quite a bit, and very much) within each dimension, where higher score=more level of intensity. The questionnaire also asked the participants to rate their overall health or quality of life within the past week on a scale of 1 to 7, where 1 is "very poor" and 7 is "excellent". Higher global health or quality of life scores indicated better overall health or quality of life. In this outcome measure, global health/quality of life scores are presented.

Time frame:
Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
Reported as:
Mean · Units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Core Questionnaire (QLQ-C30) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133: Global Health/Quality of Life
Units on a scaleCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Week 51.2 ± 19.141.3 ± 21.19-4.6 ± 16.550.3 ± 15.87
Week 9-1.9 ± 21.211.3 ± 18.77-5.6 ± 19.13-1.3 ± 14.37
Week 17-3.0 ± 19.46-1.8 ± 19.29-7.3 ± 24.45-0.8 ± 15.98
Week 253.6 ± 18.17-3.4 ± 21.030.6 ± 18.76-4.8 ± 16.79
Week 332.2 ± 19.60-0.9 ± 19.59-8.3 ± 17.68-5.0 ± 15.04
Week 41-0.9 ± 16.11-1.5 ± 16.99-9.3 ± 17.40-1.4 ± 9.95
Week 49-0.7 ± 19.530.8 ± 13.67-8.3 ± 12.73-4.2 ± 16.06
Week 613.8 ± 18.32-5.7 ± 19.26-1.2 ± 20.656.3 ± 18.48
Week 73-1.1 ± 19.640.0 ± 14.03-6.0 ± 15.002.1 ± 21.92
Week 850.9 ± 27.78-5.2 ± 7.63-3.3 ± 18.260.0
Week 97-8.3 ± 6.80-2.8 ± 6.800.0 ± 0.00—
Week 109-13.9 ± 17.350.012.5 ± 5.89—
Week 121—-8.3——
Week 133—0.0——
Other pre-specifiedChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Module (QLQ-BR23) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133

EORTC QLQ-BR23 was disease-specific module for breast cancer developed as supplement for EORTC QLQ-C30 that assessed quality of life of participants with breast cancer.Participants self-rated on frequent symptoms or problems reported by participants with breast cancer,e.g., pain/discomfort, body satisfaction, and self-esteem during past week by choosing 1 of 4 possible responses that recorded level of intensity (not at all, a little, quite a bit, and very much) within each dimension.Raw scores were then transformed to 0-100 scale for analysis and interpretation, where higher scores=more level of intensity, as per EORTC guidelines.Participants also self-rated on sexual health/interest during last 4 weeks using same scale. In this outcome measure body image functioning, sexual functioning, systemic therapy side effects, upset by hair loss parameters were assessed by EORTC QLQ-BR23 questionnaire,total score for each parameter ranged from 0-100,where higher scores=more level of intensity.

Time frame:
Baseline; Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
Reported as:
Mean · units on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Module (QLQ-BR23) at Weeks 5, 9, 17, 25, 33, 41, 49, 61, 73, 85, 97, 109, 121 and 133
units on a scaleCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Body Image Functioning: Week 51.8 ± 16.011.9 ± 19.10-6.1 ± 13.922.2 ± 15.74
Body Image Functioning: Week 9-3.5 ± 12.91-0.2 ± 17.91-3.7 ± 12.512.1 ± 15.58
Body Image Functioning: Week 17-2.9 ± 20.16-3.5 ± 19.24-9.0 ± 19.341.3 ± 13.98
Body Image Functioning: Week 252.8 ± 16.55-7.4 ± 24.24-9.4 ± 16.33-0.8 ± 7.86
Body Image Functioning: Week 33-2.9 ± 22.08-5.7 ± 17.55-1.9 ± 9.11-1.8 ± 8.12
Body Image Functioning: Week 41-2.5 ± 18.76-1.3 ± 13.360.0 ± 4.174.2 ± 14.43
Body Image Functioning: Week 49-2.4 ± 19.79-5.2 ± 17.57-1.2 ± 3.151.0 ± 8.26
Body Image Functioning: Week 613.3 ± 19.94-5.7 ± 15.23-4.8 ± 6.560.0 ± 13.61
Body Image Functioning: Week 73-3.2 ± 29.70-3.2 ± 12.051.2 ± 5.754.2 ± 10.76
Body Image Functioning: Week 858.3 ± 28.05-13.5 ± 24.781.7 ± 3.73-16.7
Body Image Functioning: Week 97-5.6 ± 17.35-1.4 ± 3.40-4.2 ± 5.89—
Body Image Functioning: Week 1090.0 ± 35.360.0-8.3 ± 11.79—
Body Image Functioning: Week 121—0.0——
Body Image Functioning: Week 133—0.0——
Sexual Functioning: Week 51.9 ± 12.08-0.3 ± 13.400.3 ± 17.001.9 ± 10.16
Sexual Functioning: Week 92.3 ± 16.15-1.4 ± 16.781.3 ± 15.682.8 ± 11.73
Sexual Functioning: Week 173.3 ± 15.650.0 ± 20.217.2 ± 23.480.6 ± 12.18
Sexual Functioning: Week 251.4 ± 17.330.5 ± 19.160.0 ± 25.201.8 ± 10.96
Sexual Functioning: Week 334.0 ± 20.433.0 ± 12.057.4 ± 22.224.2 ± 12.56
Sexual Functioning: Week 412.4 ± 23.000.8 ± 15.349.3 ± 22.221.7 ± 9.46
Sexual Functioning: Week 497.1 ± 21.695.8 ± 11.189.5 ± 26.970.0 ± 0.0
Sexual Functioning: Week 617.4 ± 21.561.9 ± 20.527.1 ± 25.200.0 ± 13.61
Sexual Functioning: Week 738.3 ± 16.982.8 ± 13.919.5 ± 31.714.2 ± 8.33
Sexual Functioning: Week 857.4 ± 22.224.8 ± 15.85-6.7 ± 27.890.0
Sexual Functioning: Week 97-5.6 ± 25.466.7 ± 9.1316.7 ± 23.57—
Sexual Functioning: Week 1090.0 ± 16.670.033.3 ± 0.00—
Sexual Functioning: Week 121—0.0——
Sexual Functioning: Week 133—0.0——
Systemic Therapy Side Effects Symptoms: Week 54.5 ± 10.593.7 ± 10.067.1 ± 11.493.3 ± 10.82
Systemic Therapy Side Effects Symptoms: Week 97.5 ± 15.242.7 ± 10.246.5 ± 11.323.9 ± 10.77
Systemic Therapy Side Effects Symptoms: Week 177.5 ± 10.812.0 ± 8.797.6 ± 16.616.0 ± 12.51
Systemic Therapy Side Effects Symptoms: Week 258.3 ± 13.902.3 ± 7.355.6 ± 10.865.7 ± 16.05
Systemic Therapy Side Effects Symptoms: Week 336.5 ± 13.54-0.2 ± 9.748.5 ± 7.055.3 ± 13.10
Systemic Therapy Side Effects Symptoms: Week 418.4 ± 10.031.3 ± 9.2010.6 ± 4.632.0 ± 10.04
Systemic Therapy Side Effects Symptoms: Week 497.8 ± 10.182.5 ± 11.039.7 ± 12.787.7 ± 9.84
Systemic Therapy Side Effects Symptoms: Week 617.6 ± 11.072.5 ± 10.4514.7 ± 10.114.8 ± 6.73
Systemic Therapy Side Effects Symptoms: Week 734.9 ± 11.904.4 ± 6.2911.6 ± 10.95-1.2 ± 5.99
Systemic Therapy Side Effects Symptoms: Week 8510.7 ± 12.582.4 ± 8.829.5 ± 6.734.8
Systemic Therapy Side Effects Symptoms: Week 978.2 ± 13.523.2 ± 10.297.1 ± 10.10—
Systemic Therapy Side Effects Symptoms: Week 10914.1 ± 9.714.89.5 ± 6.73—
Systemic Therapy Side Effects Symptoms: Week 121—9.5——
Systemic Therapy Side Effects Symptoms: Week 133—4.8——
Upset by Hair Loss: Week 5-5.6 ± 19.2518.2 ± 31.140.0 ± 28.010.0 ± 24.62
Upset by Hair Loss: Week 90.0 ± 36.5123.3 ± 31.62-6.7 ± 18.693.3 ± 24.60
Upset by Hair Loss: Week 170.0 ± 21.089.5 ± 16.273.7 ± 20.030.0 ± 36.51
Upset by Hair Loss: Week 25-6.7 ± 14.9128.6 ± 35.6326.7 ± 27.89-8.3 ± 16.67
Upset by Hair Loss: Week 330.0 ± 23.57-6.7 ± 14.9120.0 ± 29.810.0 ± 0.00
Upset by Hair Loss: Week 41-16.7 ± 33.330.00 ± 0.0013.3 ± 18.2616.7 ± 23.57
Upset by Hair Loss: Week 496.7 ± 36.510.0 ± 0.011.1 ± 19.250.0 ± 0.0
Upset by Hair Loss: Week 6111.1 ± 19.2516.7 ± 23.5725.0 ± 31.91—
Upset by Hair Loss: Week 730.0 ± 0.00.040.0 ± 43.46—
Upset by Hair Loss: Week 8533.3—0.0 ± 0.0—
Upset by Hair Loss: Week 97——0.0—
Upset by Hair Loss: Week 109——0.0 ± 0.0—
Other pre-specifiedNumber of Participants With Positive Androgen Receptor (AR) Expression by Immunohistochemistry (IHC)
Time frame:
Day 1, 29, 57, 113 and 169

No measurements were reported for this outcome.

Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. A treatment emergent AE was defined as an event that emerged during the treatment period that was absent before treatment, or worsened during the treatment period relative to the pretreatment state. AEs included both serious and non-serious AEs.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
AEs59585853
SAEs1413108
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Severity of the AEs was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only the participants with treatment-emergent AEs of grade 3 (severe) or higher grade were reported in this outcome measure.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity
ParticipantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Number of Participants With Treatment-Emergent Adverse Events of Grade 3 or Higher Severity21162212
Other pre-specifiedNumber of Participants With Clinically Significant Vital Sign Abnormalities

Criteria for clinically significant vital sign abnormalities: Systolic blood pressure (SBP): absolute SBP \<90 millimeters of mercury (mmHg) and decrease from baseline (DFB) \>30 mmHg, absolute SBP\>180 mmHg and increase from baseline (IFB) \>40 mmHg, final visit or 2 consecutive visits SBP \>=20 mmHg change from baseline (CFB), most extreme post-baseline SBP \>=140 mmHg, most extreme post-baseline SBP \>=180 mmHg, most extreme SBP \>=140 mmHg and \>=20 mmHg CFB, most extreme SBP \>=180 mmHg and \>=20 mmHg CFB; diastolic blood pressure (DBP): absolute DBP \> 105 mmHg and IFB \>30 mmHg, absolute DBP \<50 mmHg and DFB \>20 mmHg, final visit or 2 consecutive visits DBP \>=15 mmHg CFB, most extreme post-baseline DBP \>=90 mmHg, most extreme post-baseline DBP \>=105 mmHg, most extreme DBP \>=90 mmHg and \>=15 mmHg CFB, most extreme DBP \>=105 mmHg and \>=15 mmHg CFB; heart rate \<50 beats per minute (BPM) and DFB \>20 BPM or heart rate \>120 BPM and IFB \>30 BPM.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (approximately up to 10.13 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Sign Abnormalities
ParticipantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Blood pressure38394325
Heart rate0200
Other pre-specifiedNumber of Participants With Clinically Significant Laboratory Abnormalities

Laboratory tests included hematology (hematocrit, hemoglobin, platelet count, red blood cell count, total neutrophils \[absolute\] and white blood cell count with differential) and serum chemistry (albumin, alkaline phosphatase, alanine aminotransferase \[ALT\], aspartate transaminase \[AST\], blood urea nitrogen and creatinine, calcium, sodium, potassium, chloride, glucose (non-fasting), lactate dehydrogenase, magnesium, phosphorus/phosphate, total bilirubin, total bicarbonate, total protein and uric acid). Clinically significant abnormality evaluation was based on clinical investigator's judgment.

Time frame:
Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (up to 3 years)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Abnormalities
ParticipantsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Number of Participants With Clinically Significant Laboratory Abnormalities0000
Other pre-specifiedProgression Free Survival (PFS): By Electronic Data Capture (EDC)

PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1 was defined \>=20 % increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first. Cht 1: Enz + Exe = Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg; Cht 2: Enz + Exe= Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg

Time frame:
From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Reported as:
Median · Months
Progression Free Survival (PFS): By Electronic Data Capture (EDC)
MonthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Progression Free Survival (PFS): By Electronic Data Capture (EDC)11.8 (7.3 to 14.6)5.8 (3.5 to 10.9)3.6 (1.9 to 5.6)3.9 (2.6 to 5.4)
Statistical analysis
  • Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 1: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.7378 · Hazard ratio (hr): 0.928 · 95% CI 0.599 to 1.438
  • Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 2: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.8817 · Hazard ratio (hr): 0.968 · 95% CI 0.632 to 1.483
Other pre-specifiedProgression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC)

PFS was defined as the time in months from randomization to the first documentation of PD or death on study due to any cause, whichever occurred first. PD according to RECIST 1.1, was defined as \>= 20% increase in the sum of diameters of the target lesions taking as a reference the smallest sum recorded since the start of treatment or unequivocal progression in non-target lesions or the appearance of 1 or more new lesions. The analysis of PFS was based on investigator assessment of disease progression. Participants who were not known to have had a PFS event at the analysis date were censored at last tumor assessment date prior to data cutoff or date of new treatment initiation, whichever occurred first.

Time frame:
From randomization until PD, last tumor assessment without PD before new antitumor treatment initiation or death due to any cause, whichever occurred first (up to 3 years)
Reported as:
Median · Months
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC)
MonthsCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
Progression Free Survival (PFS): Diagnostic Positive (DX+) Population By Electronic Data Capture (EDC)16.9 (11.0 to NA)4.3 (1.9 to 10.9)6.0 (3.5 to 16.6)5.3 (1.8 to 6.7)
Statistical analysis
  • Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 1: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.1270 · Hazard ratio (hr): 0.522 · 95% CI 0.224 to 1.217
  • Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg vs Cohort 2: Placebo + Exemestane 25 mg · Stratified log-rank · p = 0.0359 · Hazard ratio (hr): 0.370 · 95% CI 0.143 to 0.961

Adverse events

Collected over Baseline up to 30 days after the last dose of study drug or before initiation of a new antitumor treatment, whichever occurred first (up to 10.13 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Enzalutamide 160 mg + Exemestane 50 mg2/62 (3.2%)14/62 (22.6%)59/62 (95.2%)
Cohort 1: Placebo + Exemestane 25 mg8/63 (12.7%)13/63 (20.6%)57/63 (90.5%)
Cohort 2: Enzalutamide 160 mg + Exemestane 50 mg3/60 (5%)10/60 (16.7%)57/60 (95%)
Cohort 2: Placebo + Exemestane 25 mg2/60 (3.3%)8/60 (13.3%)52/60 (86.7%)
Most frequent serious events
Showing 10 of 71
Most frequent serious events
EventCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
HYPERCALCAEMIAMetabolism and nutrition disorders2/620/632/601/60
ANAEMIABlood and lymphatic system disorders0/620/631/600/60
CARDIAC FAILURE CONGESTIVECardiac disorders0/620/630/601/60
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/620/631/600/60
INTESTINAL OBSTRUCTIONGastrointestinal disorders0/620/631/600/60
DISEASE PROGRESSIONGeneral disorders0/621/631/600/60
FACIAL PAINGeneral disorders0/620/631/600/60
FATIGUEGeneral disorders0/620/631/600/60
GENERAL PHYSICAL HEALTH DETERIORATIONGeneral disorders0/620/631/600/60
CHOLECYSTITISHepatobiliary disorders0/620/631/600/60
Most frequent other events
Showing 10 of 37
Most frequent other events
EventCohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mg
NAUSEAGastrointestinal disorders24/6210/6318/6011/60
FATIGUEGeneral disorders24/6223/6321/6013/60
HOT FLUSHVascular disorders19/6214/6314/609/60
ARTHRALGIAMusculoskeletal and connective tissue disorders15/6211/6310/607/60
DIARRHOEAGastrointestinal disorders14/6210/637/6011/60
BACK PAINMusculoskeletal and connective tissue disorders11/626/634/6011/60
CONSTIPATIONGastrointestinal disorders11/627/638/608/60
VOMITINGGastrointestinal disorders11/627/636/603/60
HEADACHENervous system disorders9/626/639/6010/60
COUGHRespiratory, thoracic and mediastinal disorders10/628/632/604/60

Baseline characteristics

Intent-to-treat (ITT) population included all the participants randomly assigned to double-blind study treatment.

Age, Categorical
Age, Categorical(Participants)Cohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mgTotal
<=18 years00000
Between 18 and 65 years42323740151
>=65 years2132232096
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Enzalutamide 160 mg + Exemestane 50 mgCohort 1: Placebo + Exemestane 25 mgCohort 2: Enzalutamide 160 mg + Exemestane 50 mgCohort 2: Placebo + Exemestane 25 mgTotal
Female63646060247
Male00000
08

Study locations

135 sites
  • ATTN-Research Pharmacist
    Aurora, Colorado 80045, United States
  • University of Colorado Cancer Center - Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • University of Colorado Hospital, Anschutz Outpatient Pavilion
    Aurora, Colorado 80045, United States
  • Rocky Mountain Cancer Centers
    Colorado Springs, Colorado 80907, United States
  • Rocky Mountain Cancer Centers
    Lakewood, Colorado 80228, United States
  • Rocky Mountain Cancer Centers
    Lone Tree, Colorado 80124, United States
  • Florida Cancer Specialists
    Altamonte Springs, Florida 32701, United States
  • Florida Cancer Specialists
    Bonita Springs, Florida 34135, United States
  • Florida Cancer Specialists
    Bradenton, Florida 34209, United States
  • Florida Cancer Specialists
    Brandon, Florida 33511, United States
  • Florida Cancer Specialists
    Cape Coral, Florida 33909, United States
  • Florida Cancer Specialists
    Clearwater, Florida 33761, United States
  • Florida Cancer Specialists
    Englewood, Florida 34223, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33905, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33908, United States
  • Florida Cancer Specialists
    Gainesville, Florida 32605, United States
  • Florida Cancer Specialists
    Hudson, Florida 34667, United States
  • Florida Cancer Specialists
    Largo, Florida 33770, United States
  • Florida Cancer Specialists
    Naples, Florida 34102, United States
  • Florida Cancer Specialists
    New Port Richey, Florida 34655, United States
  • Florida Cancer Specialists
    Orange City, Florida 32763, United States
  • Florida Cancer Specialists
    Orlando, Florida 32806, United States
  • Florida Cancer Specialists
    Port Charlotte, Florida 33980, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
  • Florida Cancer Specialists
    Sarasota, Florida 34236, United States
  • Florida Cancer Specialists
    Spring Hill, Florida 34608, United States
  • Florida Cancer Specialists
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tampa, Florida 33607, United States
  • Florida Cancer Specialists
    Tavares, Florida 32778, United States
  • Florida Cancer Specialists
    Venice, Florida 34285, United States
  • Florida Cancer Specialists
    Venice, Florida 34292, United States
  • Northwestern Medical Faculty Foundation
    Chicago, Illinois 60611, United States
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • The University of Chicago Medical Center,
    Chicago, Illinois 60637, United States
  • The University of Chicago
    Chicago, Illinois 60637, United States
  • University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
    New Lenox, Illinois 60451, United States
  • Indiana University Health Hospital
    Indianapolis, Indiana 46202, United States
  • Indiana University Health Melvin and Bren Simon Cancer Center
    Indianapolis, Indiana 46202, United States
  • Investigational Drug Services
    Indianapolis, Indiana 46202, United States
  • Sidney and Lois Eskenazi Hospital
    Indianapolis, Indiana 46202, United States
  • Springmill Medical Clinic
    Indianapolis, Indiana 46290, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Minnesota Oncology Hematology, P.A
    Minneapolis, Minnesota 55404, United States
  • Abbott Northwestern Hospital
    Minneapolis, Minnesota 55407, United States
  • Allina Health System DBA Virginia Piper Cancer Institute
    Minneapolis, Minnesota 55407, United States
  • Dr.Michaela Tsai
    Minneapolis, Minnesota 55407, United States
  • The West Clinic, P.C.
    Corinth, Mississippi 38834, United States
  • The West Clinic, P.C. d/b/a West Cancer Center
    Southaven, Mississippi 38671, United States
  • Siteman Cancer Center
    City of Saint Peters, Missouri 63376, United States
  • Barnes-Jewish Hospital
    St Louis, Missouri 63110, United States
  • Washington University Infusion Center Pharmacy
    St Louis, Missouri 63110, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Siteman Cancer Center-South County
    St Louis, Missouri 63129, United States
  • Siteman Cancer Center- West County
    St Louis, Missouri 63141, United States
  • Hematology Oncology Associates of Northern NJ
    Morristown, New Jersey 07962, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45202, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45211, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45230, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45236, United States
  • Oncology Hematology Care, Inc.
    Cincinnati, Ohio 45242, United States
  • Oncology Hematology Care, Inc.
    Fairfield, Ohio 45014, United States
  • Greenville Health System
    Greenville, South Carolina 29605, United States
  • Greenville Health System
    Seneca, South Carolina 29672, United States
  • Greenville Health System
    Spartanburg, South Carolina 29307, United States
  • Tennessee Oncology, PLLC
    Franklin, Tennessee 37067, United States
  • Tennessee Oncology, PLLC
    Gallatin, Tennessee 37066, United States
  • The West Clinic, P.C. d/b/a West Cancer Center
    Germantown, Tennessee 38138, United States
  • Tennessee Oncology, PLLC
    Hermitage, Tennessee 37076, United States
  • Tennessee Oncology, PLLC
    Lebanon, Tennessee 37090, United States
  • The West Clinic, P.C. d/b/a West Cancer Center
    Memphis, Tennessee 38104, United States
  • Tennessee Oncology, PLLC
    Murfreesboro, Tennessee 37129, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37203, United States
  • The Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Vanderbilt Breast Center at One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Vanderbilt Health Pharmacy One Hundred Oaks
    Nashville, Tennessee 37204, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37207, United States
  • Tennessee Oncology, PLLC
    Nashville, Tennessee 37211, United States
  • Henry-Joyce Cancer Clinic
    Nashville, Tennessee 37232, United States
  • Tennessee Oncology, PLLC
    Shelbyville, Tennessee 37160, United States
  • Tennessee Oncology, PLLC
    Smyrna, Tennessee 37167, United States
  • Texas Oncology - Memorial City
    Houston, Texas 77024, United States
  • Texas Oncology-Longview Cancer Center
    Longview, Texas 75601, United States
  • Texas Oncology - Tyler
    Tyler, Texas 75702, United States
  • Virginia Cancer Institute
    Mechanicsville, Virginia 23116, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23230, United States
  • Virginia Cancer Institute
    Richmond, Virginia 23235, United States
  • UZA
    Edegem, Antwerpen 2650, Belgium
  • GZA
    Wilrijk, Antwerpen 2610, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • Sunnybrook Research Institute
    Toronto, Ontario M4N 3M5, Canada
  • McGill University Health Center- Cedars Cancer Center
    Montreal, Quebec H4A 3J1, Canada
  • McGill University Health Centre - Cedars Cancer Centre
    Montreal, Quebec H4A 3J1, Canada
  • Pharmacy Department
    Dublin, 4, Ireland
  • Radiology Department
    Dublin, 4, Ireland
  • St Vincent's University Hospital
    Dublin, 4, Ireland
  • Institute for Cancer Research
    Dublin, 7, Ireland
  • Mater Private Hospital
    Dublin, 7, Ireland

Showing the first 100 of 135 sites across 7 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2013 to primary completion in Sep 2016, 33 months.

Results were first posted in Feb 2018, 1 year 4 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 33 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2013
First posted
Dec 10, 2013
StartActual
Dec 16, 2013
Primary completionActual
Sep 23, 2016
CompletionActual
Aug 23, 2024
Results first posted
Feb 6, 2018
Last update
Sep 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02007512
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Dec 10, 2013
Start date
Dec 16, 2013
Primary completion
Sep 23, 2016
Completion
Aug 23, 2024
Results posted
Feb 6, 2018
Last update
Sep 2, 2025

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion